The drugs, developed by Gilead Sciences, represent the first direct-acting antiviral treatments approved for this patient population.
Harvoni and Sovaldi can treat six major strains of hepatitis C and work by preventing the virus from multiplying.
“These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents,” said Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
More articles on supply chain:
Survey: 26% of supply chain leaders considering self-distribution
PhRMA blames insurers for high drug costs in new ad
Amazon brings fuel cell technology to warehouses: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
